Results 81 to 90 of about 4,011 (178)

Oral Treprostinil is Associated with Improved Survival in FREEDOM-EV and its Open-Label Extension [PDF]

, 2023
\ua9 2023, The Author(s).Introduction: In the event-driven FREEDOM-EV trial, oral treprostinil delayed clinical worsening in patients with pulmonary arterial hypertension (PAH).
Rahaghi F, Elwing J, Balasubramanian V, Shen J, Grover R, White RJ, Grunig E, Rosenkranz S, Lordan J, Pepke-Zaba J, Broderick M, Yuanhua Y, Deng C, Vonk M, Ousmanou A, Cadaret L, Seaman S, Vizza CD, Yao H, Hage A, Yu Z   +20 more
core  

The influence of sex on the in vivo and in vitro effects of treprostinil in pulmonary arterial hypertension [PDF]

, 2017
Pulmonary arterial hypertension (PAH) is a progressive and fatal vascular disease that is more prevalent in women than men. The underlying pathology of the disease involves various factors, including genetic risk (i.e. bone morphogenetic protein receptor
Murphy, Gerard William
core  

Data from: Mechanism of anti-remodelling action of treprostinil in human pulmonary arterial smooth muscle cells

, 2018
Treprostinil is applied for pulmonary arterial hypertension (PAH) therapy. However, the mechanism by which the drug achieves its beneficial effects in PAH vessels is not fully understood.
Klepetko, Walter, Lambers, Christopher, Oberndorfer, Felicitas, Kornauth, Christoph, Boehm, Panja M., Tamm, Michael, Meyer, Elias Laurin, Roth, Michael   +7 more
core   +1 more source

322 Subcutaneous treprostinil in pediatric idiopathic pulmonary arterial hypertension [PDF]

, 2010
BackgroundTherapeutic options at time of worsening remain unclear in children who do worse but remain in functional class III while being on combined oral therapy with endothelin receptor antagonists and PDE-5 inhibitors.ObjectiveTo evaluate the use of a
Bonnet, Damien, Bourges-Petit, Elisabeth, Lévy, Marilyne, Bajolle, Fanny, Del Cerro, Maria Jesus   +4 more
core   +1 more source

Subcutaneous treprostinil in congenital heart disease-related pulmonary arterial hypertension

, 2018
ObjectiveTo assess the efficacy and safety of subcutaneous treprostinil in adult patients with congenital heart disease (CHD)-associated pulmonary arterial hypertension (PAH) after 12 months of treatment.MethodsConsecutive adult patients with CHD–PAH ...
Roela Sadushi-Kolici, Dora Kohalmi, Nika Skoro-Sajer, Monika Kaldararova, Harald Gabriel, David S Celermajer, Olga Hajnalka Balint, Christian Gerges, Helmut Baumgartner, Mario Gerges, Iveta Simkova, Johannes Jakowitsch, Irene Marthe Lang   +12 more
core   +1 more source

Intravenous treprostinil via an implantable pump in pediatric pulmonary arterial hypertension

Pulmonary Circulation, 2018
Intravenous prostacyclin-based therapy improves survival in children with pulmonary arterial hypertension (PAH), but is typically administered via an external infusion pump, which places a considerable burden on the patient.
Susanna Desole, Manuel Jonas Richter, Alexander Heine, Ralf Ewert   +3 more
doaj   +1 more source

The Second-Generation PGI2 Analogue Treprostinil Fails to Chemoprevent Tumors in a Murine Lung Adenocarcinoma Model

, 2017
Prostacyclin (prostaglandin I2, PGI2) overproduction in FVB/N mice prevents the formation of carcinogen and tobacco smoke–induced adenomas, and administration of the oral prostacyclin analogue iloprost to wild-type mice also prevented carcinogen-induced ...
Kevin Choo, Robert L. Keith, Lori Dwyer-Nield, Micah Friedman, Melissa L. New, Gregory A. Hickey, Meredith A. Tennis, Mark Geraci, Debbie G. McArthur   +8 more
core   +1 more source

Understanding Treprostinil pharmacology in the heart: from whole organ to cellular nanodomains

Treprostinil, a prostacyclin analogue, is known for alleviating pulmonary arterial hypertension (PAH), a condition characterised by chronic pulmonary vessel obstruction.
Judina, Aleksandra
core   +1 more source

Study Design and Rationale for the TETON-PPF Phase 3, Randomized, Controlled Clinical Trial of Inhaled Treprostinil in the Treatment of Progressive Pulmonary FibrosisTake-Home Points

CHEST Pulmonary
Background: Progressive pulmonary fibrosis (PPF) affects a group of patients with various underlying interstitial lung diseases (ILDs) who develop progressive fibrosis and exhibit a similar disease course to patients with idiopathic pulmonary fibrosis ...
Steven D. Nathan, MD, Juergen Behr, MD, Vincent Cottin, MD, Lisa Lancaster, MD, Peter Smith, PharmD, CQ Deng, PhD, Natalie Breytenbach, PharmD, Heidi Bell, MD, Leigh Peterson, PhD, Kevin R. Flaherty, MD   +9 more
doaj   +1 more source

Dosing characteristics of oral treprostinil in real-world clinical practice

Pulmonary Circulation, 2018
Pharmacokinetic studies with oral treprostinil demonstrate that three times daily (TID) dosing reduces peak-to-trough plasma trepostinil fluctuations compared with twice daily (BID) dosing.
Vijay P. Balasubramanian, Chad R. Messick, Meredith Broderick, Andrew C. Nelsen   +3 more
doaj   +1 more source